3805 Old Easton Road
Doylestown, PA 18902
United States
617 463 9385
https://www.aprea.com
Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 7
Name | Titel | Zahlen | Ausgeübt | Geburtsjahr |
---|---|---|---|---|
Dr. Oren Gilad Ph.D. | Co-Founder, CEO, President & Director | 796,95k | N/A | 1968 |
Mr. John P. Hamill CPA | Senior VP, CFO, Principal Accounting Officer & Secretary | 610,23k | N/A | 1964 |
Dr. Dansu Li Ph.D. | Head of Technology | N/A | N/A | N/A |
Dr. Lars B. Abrahmsen Ph.D. | Senior VP & Chief Scientific Officer | N/A | N/A | 1957 |
Mr. Brian Wiley | Senior Vice President of Corporate Development & Strategy | N/A | N/A | 1968 |
Dr. Michel Afargan Ph.D. | Head of Pharmacology Development | N/A | N/A | N/A |
Mr. Ze'ev Weiss B.Sc., C.P.A. | Chief Business Advisor | N/A | N/A | 1962 |
Dr. Nadeem Q. Mirza M.D., M.P.H. | Chief Medical Officer | N/A | N/A | N/A |
Ms. Andrea Epstein | Controller | N/A | N/A | N/A |
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.
Aprea Therapeutics, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 8. Die grundlegenden Scores sind Audit: 3, Vorstand: 7, Shareholderrechte: 8, Kompensation: 9.